Granules India’s arm enters into agreement with Par Pharmaceutical

21 Jan 2016 Evaluate

Granules India’s wholly owned subsidiary -- Granules USA has entered into an agreement with Par Pharmaceutical Inc., a subsidiary of Endo International plc, to market the generic version of OTC omeprazole and sodium bicarbonate in North America following approval by the U.S. Food and Drug Administration's, which is currently expected in July 2016.

Par Pharmaceutical's omeprazole and sodium bicarbonate is the generic equivalent of Merck/MSD Consumer Care, Inc's Zegerid OTC. Omeprazole is a proton pump inhibitor (PPI) that decreases the production of stomach acid. Sodium bicarbonate is an antacid that raises stomach pH to keep the omeprazole from breaking down in stomach acid.

Granules India is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets. The company's global presence extends to over 300 customers in 60 countries through offices in India, U.S., U.K., China and Colombia.

Granules India Share Price

593.90 -12.00 (-1.98%)
10-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.05
Dr. Reddys Lab 1354.20
Cipla 1470.05
Lupin 2190.50
Zydus Lifesciences 1004.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.